EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-alpha inhibitors: a systematic review and meta-analysis

Wen-Ting Wu, Ming-Che Chiang iD, Yu-Chen Huang

Clinical and Experimental Dermatology · 24.04.2025 · 50 (5) · 968-980

DOI: 10.1093/ced/llae503 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 29.11.2024. Verfasst von Wen-Ting Wu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Psoriasis, Neoplasms, Tumor Necrosis Factor-alpha, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Taipei Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The relationship between tumour necrosis factor-alpha inhibitors (TNFis) and cancer risk is complex, given their pivotal role in managing chronic inflammatory conditions. Persistent concerns about TNFi therapy potentially increasing cancer risk necessitate a thorough understanding of its long-term effects on cancer development in patients with psoriasis to guide therapeutic decision making.

Objectives

To evaluate the association between long-term TNFi therapy and cancer risk in patients with psoriasis in a systematic review and meta-analysis.

Methods

Data were collected from PubMed, Embase and the Cochrane Library, from their inception to 1 January 2024. The studies included adults with psoriasis or psoriatic arthritis receiving an TNFi, presenting standardized incidence ratio (SIR) data for cancer. Data extraction followed PRISMA guidelines, with independent extraction by two authors, and pooled data synthesis was conducted using a random-effects model. The primary outcomes were SIRs for all cancers excluding nonmelanoma skin carcinoma (NMSC) and for NMSC itself. The secondary outcome was SIRs for specific cancer types.

Results

We reviewed 13 studies, including 8 new studies and 5 from a previous meta-analysis. Of the 13 studies, only 8 were included in the meta-analysis comprising a total of 32 765 patients with psoriasis. The pooled results showed no increased risk of cancers for the categories: all cancers excluding NMSC; melanoma; lymphoma; prostate cancer; and breast cancer among individuals receiving long-term TNFi therapy for psoriasis compared with the general population. However, subgroup analysis found an elevated risk of NMSC in patients with psoriatic arthritis and a significant increase in the risk of squamous cell carcinoma (SCC) among patients with psoriasis treated with TNFis compared with the general population [SIR 1.84, 95% confidence interval (CI) 1.16–2.92 and SIR 2.84, 95% CI 1.64–4.91, respectively].

Conclusions

Our systematic review and meta-analysis indicate that most cancers examined did not demonstrate an increased risk following long-term TNFi therapy in patients with psoriasis. However, for patients with psoriatic arthritis or those at high risk of SCC, these findings underscore the importance of personalized treatment strategies that weigh individual risks and benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisNeoplasmsTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsHumansArthritis, PsoriaticRisk Factors

Substanzen

Tumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Research Center of Big Data and Meta-analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Ming-Che Chiang

Förderung

  • Taipei Medical University

Zitieren

APA

Wu, W. T., Chiang, M. C., & Huang, Y. C. (2025). The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-alpha inhibitors: a systematic review and meta-analysis. Clinical and Experimental Dermatology, 50(5), 968-980. https://doi.org/10.1093/ced/llae503

Vancouver

Wu WT, Chiang MC, Huang YC. The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-alpha inhibitors: a systematic review and meta-analysis. Clinical and Experimental Dermatology. 2025;50(5):968-980. doi:10.1093/ced/llae503

BibTeX
@article{Wu2025,
  author = {Wu, Wen-Ting and Chiang, Ming-Che and Huang, Yu-Chen},
  title = {The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-alpha inhibitors: a systematic review and meta-analysis},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  volume = {50},
  number = {5},
  pages = {968--980},
  doi = {10.1093/ced/llae503}
}
Kostenlos starten →